D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00083876
Recruitment Status : Completed
First Posted : June 4, 2004
Last Update Posted : July 2, 2010
Celgene Corporation
Information provided by:
University of Arkansas